HIGHLIGHTS
- who: Kingdom. JHEOR. and collaborators from the Cost-effective, Ribociclib, Palbociclib, HR+/HER2-, advanced breast cancer, UK have published the Article: Journal of Health Economics and Outcomes Research, in the Journal: (JOURNAL)
- what: Methods: A cohort-based partitioned survival model was developed to evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with HR+/HER2- advanced breast cancer over a lifetime horizon. The analysis was carried out from a National Health Services and Personal Social Services perspective and results are presented in incremental costs per quality adjusted life . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.